AI assistant
IMPEDIMED LIMITED — Board/Management Information 2016
Feb 28, 2016
65135_rns_2016-02-28_bd1eac3c-ef90-4ebb-bea8-f49df23dea09.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [193 x 43] intentionally omitted <==
29 February 2016
ASX ANNOUNCEMENT
IMPEDIMED ANNOUNCES CHANGES TO THE BOARD OF DIRECTORS
Brisbane, Australia - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition today announced the retirement of Mr Jim Hazel, who will step down from his positions of Non-Executive Director and Chair of Audit and Risk Committee, effective 1 March 2016.
The company is also pleased to announce that Ms Elizabeth Gaines will join the ImpediMed Board as a non-executive Director and Chair of the Audit and Risk Committee, effective 1 March 2016.
Ms Gaines was most recently the CEO, and previously CFO / COO of Helloworld (ASX:HLO), an ASX listed travel distribution business. Her executive career includes leadership and senior finance roles in Australia and internationally spanning financial services, infrastructure, media and travel distribution. Ms Gaines is a member of Chartered Accountants Australia and New Zealand, Australian Institute of Company Directors and Chief Executive Women.
Ms Gaines is a Non-Executive Director of Fortescue Metals Group Limited (ASX:FMG), NextDC Limited (ASX:NXT) and effective 1 March 2016, Nine Entertainment Co Limited, (ASX:NEC).
Ms Cherrell Hirst, Chair of ImpediMed said: “I would firstly likely to thank Jim for his unwavering support and contribution to ImpediMed over the past ten years. The company has undergone immense change in this time and has not been without its challenges; Jim’s guidance and commitment throughout his tenure has been greatly valued.
“On behalf of my fellow Directors, I am very pleased to welcome Elizabeth to the ImpediMed Board. Her financial management expertise and breadth of commercial experience will augment the Board and leadership as the needs of the organization become more complex in line with its growing sales and presence in the US, and its expansion into new indications.”
Ms Gaines said, “I am very pleased to be joining ImpediMed at this exciting stage. The company has proven its ability to successfully commercialise its technology and I look forward to working with the company as it now executes on its strategy to move into new markets and drive additional value from its technology.”
- ENDS -
For further information contact: Leanne Ralph, ImpediMed Company Secretary T: +61 414 731 082 E: [email protected]
Kyahn Williamson, Buchan Investor and Media Relations T: +61 3 9866 4722 E: [email protected]
About ImpediMed
Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.